Pfizer Pipeline

As of November 8, 2013
As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 2 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of November 8, 2013.

Visit Pfizer.com/pipeline, Pfizer’s online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Pipeline Snapshot</td>
<td>4</td>
</tr>
<tr>
<td>Cardiovascular &amp; Metabolic Diseases</td>
<td>5</td>
</tr>
<tr>
<td>Inflammation &amp; Immunology</td>
<td>6</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>7</td>
</tr>
<tr>
<td>Oncology</td>
<td>8</td>
</tr>
<tr>
<td>Vaccines</td>
<td>9</td>
</tr>
<tr>
<td>Other Areas of Focus</td>
<td>10</td>
</tr>
<tr>
<td><em>(including Biosimilars and Rare Diseases)</em></td>
<td></td>
</tr>
</tbody>
</table>
Pfizer Pipeline represents progress of R&D programs as of August 9, 2013. Included are 55 NMEs, 17 additional indications, plus 4 biosimilars.

- Phase 1: 31 programs
- Phase 2: 24 programs
- Phase 3: 20 programs
- In Reg.: 6 programs
- Total: 81 programs

Recent Approval:
- Duavee for Treatment of Menopausal Vasomotor Symptoms and Osteoporosis (US)

Pfizer Pipeline represents progress of R&D programs as of November 8, 2013. Included are 59 NMEs, 18 additional indications, plus 4 biosimilars.

- Phase 1: 29 programs
- Phase 2: 24 programs
- Phase 3: 17 programs
- In Reg.: 6 programs
- Total: 76 programs

0 programs discontinued since last update

4 projects discontinued since last update
# Pfizer Pipeline – November 8, 2013

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Compound Name</th>
<th>Mechanism of Action (Phase 2 through regulatory approval)</th>
<th>Indication</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiovascular and Metabolic Diseases</strong></td>
<td>Eliquis (apixaban)</td>
<td>Factor Xa Inhibitor</td>
<td>Venous Thromboembolism Prevention (U.S.)</td>
<td>Registration</td>
</tr>
<tr>
<td></td>
<td>Eliquis (apixaban)</td>
<td>Factor Xa Inhibitor</td>
<td>Venous Thromboembolism Treatment</td>
<td>Phase 3</td>
</tr>
<tr>
<td>▶ ertugliflozin (PF-04971729)</td>
<td>SGLT-2 Inhibitor</td>
<td></td>
<td>Diabetes Mellitus-Type 2</td>
<td>Phase 3</td>
</tr>
<tr>
<td>▶ bococizumab (RN316) (PF-04950615)</td>
<td>PCSK9 Inhibitor</td>
<td></td>
<td>Hypercholesterolemia (Biologic)</td>
<td>Phase 3</td>
</tr>
<tr>
<td>PF-00489791</td>
<td>PDE5 Inhibitor</td>
<td></td>
<td>Diabetic Nephropathy</td>
<td>Phase 2</td>
</tr>
<tr>
<td>PF-04634817</td>
<td>CCR2/5 Antagonist</td>
<td></td>
<td>Diabetic Nephropathy</td>
<td>Phase 2</td>
</tr>
<tr>
<td>PF-04937319</td>
<td>Partial Glucokinase Activator</td>
<td></td>
<td>Diabetes Mellitus-Type 2</td>
<td>Phase 2</td>
</tr>
<tr>
<td>PF-05175157</td>
<td></td>
<td></td>
<td>Diabetes Mellitus-Type 2</td>
<td>Phase 1</td>
</tr>
<tr>
<td>PF-05231023</td>
<td></td>
<td></td>
<td>Diabetes Mellitus-Type 2 (Biologic)</td>
<td>Phase 1</td>
</tr>
<tr>
<td>PF-06282999</td>
<td></td>
<td></td>
<td>Acute Coronary Syndrome</td>
<td>Phase 1</td>
</tr>
<tr>
<td>PF-06291874</td>
<td></td>
<td></td>
<td>Diabetes Mellitus-Type 2</td>
<td>Phase 1</td>
</tr>
<tr>
<td>RN317 (PF-05335810)</td>
<td></td>
<td></td>
<td>Hypercholesterolemia (Biologic)</td>
<td>Phase 1</td>
</tr>
</tbody>
</table>

- Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

<p>| New Molecular Entity                  | New Indication or Enhancement           |</p>
<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Compound Name</th>
<th>Mechanism of Action (Phase 2 through regulatory approval)</th>
<th>Indication</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inflammation and Immunology</td>
<td>Xeljanz (tofacitinib)</td>
<td>JAK Inhibitor</td>
<td>Psoriasis (Oral)</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Xeljanz (tofacitinib)</td>
<td>JAK Inhibitor</td>
<td>Ulcerative Colitis</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Xeljanz (tofacitinib)</td>
<td>JAK Inhibitor</td>
<td>Psoriatic Arthritis</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>anrukinzumab (IMA-638)</td>
<td>IL-13 Inhibitor</td>
<td>Ulcerative Colitis (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PD-0360324</td>
<td>M-CSF Inhibitor</td>
<td>Sarcoidosis, *Lupus (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-00547659</td>
<td>MAdCAM Inhibitor</td>
<td>Crohn’s Disease, Ulcerative Colitis (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-04171327</td>
<td>Selective Glucocorticoid Receptor Modulator</td>
<td>Rheumatoid Arthritis</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-04236921</td>
<td>IL-6 Inhibitor</td>
<td>Crohn’s Disease, Lupus (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-05285401</td>
<td>Multipotent Adult Progenitor Cell</td>
<td>Ulcerative Colitis (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-06473871 (EXC 001)</td>
<td>CTGF Inhibitor</td>
<td>Dermal Scarring</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PH-797804</td>
<td>P38 Inhibitor</td>
<td>Chronic Obstructive Pulmonary Disease</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>Xeljanz (tofacitinib)</td>
<td>JAK Inhibitor</td>
<td>Ankylosing Spondylitis, Psoriasis (Topical), Crohn’s Disease</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>Dekavil</td>
<td></td>
<td>Rheumatoid Arthritis (Biologic)</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-03715455</td>
<td></td>
<td>Chronic Obstructive Pulmonary Disease</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-04965842</td>
<td></td>
<td>Lupus</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-06342674</td>
<td></td>
<td>Diabetes Mellitus-Type 1 (Biologic)</td>
<td>Phase 1</td>
</tr>
</tbody>
</table>

*Note: Additional indications in Phase 1
<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Compound Name</th>
<th>Mechanism of Action (Phase 2 through regulatory approval)</th>
<th>Indication</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>Celebrex</td>
<td>COX-2</td>
<td>Chronic Pain (U.S.)</td>
<td>Registration</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>Remoxy</td>
<td>Mu-type opioid receptor (MOR-1) Agonist</td>
<td>Moderate to Severe Pain (U.S.)</td>
<td>Registration</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>ALO-02 Oxycodone-naltrexone core</td>
<td>Mu-type opioid receptor (MOR-1) Agonist</td>
<td>Moderate to Severe Pain</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>Lyrica</td>
<td>Alpha-2 Delta Ligand</td>
<td>Peripheral Neuropathic Pain</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>Lyrica</td>
<td>Alpha-2 Delta Ligand</td>
<td>CR (once a day dosing)</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>tanezumab</td>
<td>Nerve Growth Factor Inhibitor</td>
<td>OA Signs and Symptoms (on clinical hold)</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>▶ PF-02545920</td>
<td>PDE10 Inhibitor</td>
<td>Huntington’s Disease, Adjunctive Treatment for Schizophrenia</td>
<td>Phase 2</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>PF-03049423</td>
<td>PDE5 Inhibitor</td>
<td>Stroke Recovery</td>
<td>Phase 2</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>PF-04360365 (ponezumab)</td>
<td>Beta Amyloid Inhibitor</td>
<td>Cerebral Amyloid Angiopathy (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>PF-05212377 (SAM-760)</td>
<td>5HT6 Antagonist</td>
<td>Alzheimer’s Disease</td>
<td>Phase 2</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>▶ PF-06412562</td>
<td>Nerve Growth Factor Inhibitor</td>
<td>Cancer Pain (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>PF-04958242</td>
<td></td>
<td>Schizophrenia</td>
<td>Phase 1</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>PF-05089771</td>
<td></td>
<td>Chronic Pain</td>
<td>Phase 1</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>PF-05236812 (AAB-003)</td>
<td></td>
<td>Alzheimer’s Disease (Biologic)</td>
<td>Phase 1</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>PF-06273340</td>
<td></td>
<td>Acute and Chronic Pain</td>
<td>Phase 1</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>PF-06305591</td>
<td></td>
<td>Chronic Pain</td>
<td>Phase 1</td>
</tr>
<tr>
<td>Neuroscience &amp; Pain</td>
<td>▶ PF-06412562</td>
<td></td>
<td>Cognitive Disorder</td>
<td>Phase 1</td>
</tr>
<tr>
<td>Therapeutic Area</td>
<td>Compound Name</td>
<td>Mechanism of Action (Phase 2 through regulatory approval)</td>
<td>Indication</td>
<td>Phase</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------</td>
<td>----------------------------------------------------------</td>
<td>------------</td>
<td>-------</td>
</tr>
<tr>
<td>Oncology</td>
<td>dacomitinib (PF-00299804)</td>
<td>pan-HER Inhibitor</td>
<td>Previously Treated Advanced Non-Small Cell Lung Cancer</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>dacomitinib (PF-00299804)</td>
<td>pan-HER Inhibitor</td>
<td>1st Line Non-Small Cell Lung Cancer</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Inlyta (axitinib)</td>
<td>VEGF Tyrosine Kinase Inhibitor</td>
<td>Renal Cell Carcinoma Adjuvant (Asia only)</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>inotuzumab ozogamicin</td>
<td>CD22-targeted cytotoxic agent</td>
<td>Acute Lymphoblastic Leukemia (Biologic)</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>palbociclib (PD-0332991)</td>
<td>CDK 4,6 Kinase Inhibitor</td>
<td>1st Line Advanced Breast Cancer, *Cancer</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>► palbociclib (PD-0332991)</td>
<td>CDK 4,6 Kinase Inhibitor</td>
<td>Recurrent Advanced Breast Cancer</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Sutent</td>
<td>Multiple Tyrosine Kinase Inhibitor</td>
<td>Renal Cell Carcinoma Adjuvant</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Xalkori (crizotinib)</td>
<td>c-MET-ALK Inhibitor</td>
<td>ALK-Positive 1st and 2nd Line (supports potential full approval in the U.S.) Non-Small Cell Lung Cancer, *Cancer</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>dacomitinib (PF-00299804)</td>
<td>pan-HER Inhibitor</td>
<td>Cancer</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>Inlyta (axitinib)</td>
<td>VEGF Tyrosine Kinase Inhibitor</td>
<td>Liver Cancer</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>► PF-03446962</td>
<td>ALK1 Inhibitor</td>
<td>2nd Line Hepatocellular Carcinoma (Biologic)</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-05212384</td>
<td>PI3K Inhibitor</td>
<td>Endometrial Cancer, *Cancer</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PD-0325901</td>
<td>PI3K Inhibitor</td>
<td>Cancer (in combination with PF-05212384)</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-03084014</td>
<td></td>
<td>Cancer</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-04449913</td>
<td></td>
<td>Acute Myelocytic Leukemia</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-05082566</td>
<td></td>
<td>Cancer (Biologic)</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>► PF-06263507</td>
<td></td>
<td>Cancer</td>
<td>Phase 1</td>
</tr>
</tbody>
</table>

* Note: Additional indications in Phase 1

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com
<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Compound Name</th>
<th>Mechanism of Action (Phase 2 through regulatory approval)</th>
<th>Indication</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccines</td>
<td>MnB rLP2086 (PF-05212366)</td>
<td>Prophylactic Vaccine</td>
<td>Adolescent and Young Adult Meningitis B</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF-06290510)</td>
<td>Prophylactic Vaccine</td>
<td>Staph Aureus</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>PF-05402536</td>
<td></td>
<td>Smoking Cessation</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-06425090</td>
<td></td>
<td>Clostridium Difficile Colitis</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-06444752</td>
<td></td>
<td>Asthma</td>
<td>Phase 1</td>
</tr>
</tbody>
</table>

New Molecular Entity
# Pfizer Pipeline – November 8, 2013 (cont’d)

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Compound Name</th>
<th>Mechanism of Action (Phase 2 through regulatory approval)</th>
<th>Indication</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Other Areas of Focus</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Rare Diseases)</td>
<td>tafamidis meglumine</td>
<td>Transthyretin (TTR) Dissociation Inhibitor</td>
<td>Transthyretin familial amyloid polyneuropathy (U.S.)</td>
<td>Registration</td>
</tr>
<tr>
<td></td>
<td>Rivipansel (GMI-1070)</td>
<td>Pan-Selectin Antagonist</td>
<td>Vaso-occlusive crisis associated with Sickle Cell Disease</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>►PF-05230907</td>
<td></td>
<td>Intracerebral Hemorrhage</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-05280602</td>
<td></td>
<td>Hemophilia (Biologic)</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-06252616</td>
<td></td>
<td>Muscular Dystrophies (Biologic)</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-06687859</td>
<td></td>
<td>Spinal Muscular Atrophy</td>
<td>Phase 1</td>
</tr>
<tr>
<td>(Biosimilars)</td>
<td>PF-05280014 (a potential trastuzumab Biosimilar*)</td>
<td></td>
<td>Metastatic Breast Cancer (Biosimilar)</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-05280586 (a potential rituximab Biosimilar*)</td>
<td></td>
<td>Rheumatoid Arthritis (Biosimilar)</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-06410293 (a potential adalimumab Biosimilar*)</td>
<td></td>
<td>Rheumatoid Arthritis (Biosimilar)</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>PF-06438179 (a potential infliximab Biosimilar*)</td>
<td></td>
<td>Rheumatoid Arthritis (Biosimilar)</td>
<td>Phase 1</td>
</tr>
<tr>
<td>Other Areas of Focus</td>
<td>Conjugated estrogens/bazedoxifene</td>
<td>Tissue Selective Estrogen Complex</td>
<td>Menopausal Vasomotor Symptoms and Osteoporosis (EU)</td>
<td>Registration</td>
</tr>
<tr>
<td></td>
<td>Viviant</td>
<td>Selective Estrogen Receptor Modulator</td>
<td>Osteoporosis Treatment and Prevention (U.S.)</td>
<td>Registration</td>
</tr>
<tr>
<td></td>
<td>Zithromax/chloroquine</td>
<td>5-OS Ribosome Inhibitor</td>
<td>Malaria</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>bosutinib</td>
<td>Abl and src-family kinase Inhibitor</td>
<td>Autosomal Dominant Polycystic Kidney Disease</td>
<td>Phase 2</td>
</tr>
</tbody>
</table>

* Biosimilarity has not yet been established by regulators and is not claimed.

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com